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The retinal pigment epithelium (RPE) is essential for eye
development by interacting with the overlaying neuroepithe-
lium. Regulatory sequences of the gene encoding for tyrosi-
nase-related protein 1 (TRP-1), linked to the lacZ reporter
gene, lead to strong and specific b-galactosidase expression in
the RPE. W e asked how the oncogene ret would affect this
epithelial cell type during mouse development. W e used the
TRP-1 promoter to express ret in the developing RPE, and
obtained transgenic mouse lines, which showed mild to
severe microphthalmia. During development, the RPE
changed to a stratified epithelium with reduced or absent
pigmentation from E10.5 onward. In addition, proliferation of
RPE cells and tumor formation were observed from E12.5
onward. These early eventsprevent closure of choroid fissure
and lead to microphthalmia and secondary malformations
after birth. W e conclude that ret transgene expression in the
RPE prevents normal differentiation of this epithelial layer
and induces proliferation and tumor formation. The appear-
ance of the microphthalmicphenotype underlinesthe require-
ment of a normally developed RPE for eye development. Int.
J. Cancer 80:600–605, 1999.
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The optic cup is a derivative of the prosencephalic neuroepithe-
lium and originally comprises 2 layers. The inner layer gives rise to
the multilayered neuroretina and the outer layer forms the retinal
pigment epithelium (RPE), which consists of a single layer of
pigment cells (for review see Zhao et al., 1997). Within the RPE,
tyrosinase and tyrosinase-related proteins 1 and 2 (TRP-1, TRP-2)
are important for pigmentation and are involved in the biosynthesis
of melanin. These 3 genes are also expressed later in development
in pigment cells derived from the neural crest, the melanocytes.
The promoters of tyrosinase, TRP-1 and TRP-2 all direct transgene
expression to the developing RPE, starting at about E9.5 (TRP-2)
or E10.5 (tyrosinase and TRP-1) (MacKenzie et al., 1997; Ray-
mond and Jackson, 1995; Tief et al., 1996). The TRP-2 promoter
appears to be the strongest and earliest active, with expression in
melanoblasts detected from the time of their appearance at E10.5
(MacKenzie et al., 1997). In contrast, expression from the TRP-1
promoter is nearly undetectable in melanocytes of transgenic mice
(Penna et al., 1998; Raymond and Jackson, 1995), in contrast to its
efficient expression in developing RPE. Transcription factors such
as Otx-2 or microphthalmia (Mi) are specifically expressed in the
RPE and have been shown to be important for differentiation and
expression of pigmentation genes. In the adult, the RPE is essential
for function of photoreceptors in the neuroretina. The RPE
provides physical protection, regulates the flow of substances to
and from the neuroretina and phagocytozes shed photoreceptors.
Image sharpness is improved by the presence of the pigment
melanin, leading to absorption of light penetrating the sclera.
Ablation of the RPE, as demonstrated in transgenic mice, interferes
with and blocks differentiation and maintenance of the neuroretina
(Raymond and Jackson, 1995).
Different mouse mutations cause degeneration of the neuro-
retina, as has been described for rd (retinal degeneration) or
retinitis pigmentosa (Humphries et al., 1997). Defects in the RPE
have been reported in a mouse model for gyrate atrophy. Here,
deficiency of ornithine d-aminotransferase (OAT) led to progres-
sive retinal degeneration over the first year of life with accumula-
tion of phagosomes and crystalloid inclusions in the RPE (Wang et
al., 1996). In mice carrying mutations of the Mi gene, retinal
degeneration, reduced eye pigmentation and small eyes are also
observed (Moore, 1995). The Mi protein is a transcription factor of
the basic helix-loop-helix-leucine zipper family, which binds DNA
as homo- or heterodimer with members of the same transcription
factor family (Moore, 1995). It is essential for differentiation of
pigmented cells including the RPE, and is able to activate
transcription of tyrosinase and TRP-1 genes (for review see Zhao et
al., 1997).
The RET proto-oncogene encodes a receptor tyrosine kinase,
which was originally identified as a transforming gene by transfec-
tion of T-cell lymphoma DNA into NIH3T3 cells (Takahashi et al.,
1985). RET is expressed in a variety of cell lineages in the
developing central and peripheral nervous system and the excretory
system. Mice homozygous for targeted deletion of the RET locus
die soon after birth. This revealed that RET is essential for renal
organogenesis and enteric neurogenesis (Schuchardt et al., 1994).
In humans, mutations of RET are responsible for the MEN2
syndromes (multiple endocrine neoplasia type 2A and type 2B,
familial medullar thyroid carcinoma, medullar thyroid carcinoma)
and Hirschsprung disease. These diseases are regarded as neurocris-
topathies, since they affect neural crest-derived cells and their
derivatives. However, there is also evidence for effects on other cell
lineages, as demonstrated by parathyroid hyperplasia in MEN2A
patients (for review see Edery et al., 1997). A receptor complex
comprised of TrnR1 [transforming growth factor b-related neuro-
trophic factor 1, glial cell line-derived neurotrophic factor receptor
a (GDNFRa)] and RET has recently been identified and found to
be capable of mediating signaling of both GDNF and neurturin. An
additional coreceptor, TrnR2, can replace TrnR1 in this receptor
complex (e.g., Baloh et al., 1997). In vitro expression of an
epidermal growth factor (EGF) receptor/RET chimeric protein has
revealed that the cytoplasmic domain containing the tyrosine
kinase activity is sufficient to provide RET-specific signaling
(Santoro et al., 1994).
Several RET fusion proteins have been isolated, all of which are
dominant oncogenic forms of RET, i.e., RET/PTC1, RET/PTC2,
RET/PTC3. These fusion proteins originate from somatic rearrange-
ments of the cytoplasmic tyrosine kinase domain of RET with
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different N-termini (H4, RIa and ELE1). Following dimerization
of the N-termini, RET tyrosine kinase becomes constitutively
activated (for review see Edery et al., 1997). The ret transforming
gene is a fusion gene of the human RET proto-oncogene and the
zinc finger-containing rfp gene (RET finger protein), a transcrip-
tional activator, and arose as rearrangement in a transfection assay
(Cao et al., 1997; Takahashi et al., 1985). The ret chimeric protein
has also been proposed to function as constitutively activated RET
tyrosine kinase, caused by ligand-independent dimerization (Cao et
al., 1997). We used this oncogene to directly affect the RPE, and
asked if and how it would act on this specialized cell type. To target
ret expression to the RPE, we used 4 kb of the promoter of the gene
encoding TRP-1, a protein involved in pigment synthesis (Ray-
mond and Jackson, 1995). We first showed by using a reporter gene
that this promoter specifically targets expression to the RPE in
transgenic mice. Expression of ret transforming gene in the RPE
results in microphthalmia and tumor formation. The changes in the
RPE, which is thickened and largely unpigmented, severely affect
the development of the eye.
MATERIAL AND METHODS
TRP-1/lacZ fusion construct
The TRP-1 first intron was isolated by polymerase chain reaction
(PCR) (primer 1: 58-agagtcgacctggcatcaggggaaaagc-38; primer 2:
58-agacctcgagtcttctcgagcaagagtt-38), which placed a SalI site 58
and a XhoI site 38 to the intron. This fragment was inserted into the
SalI site within the pUC polylinker of the lacZ reporter vector
pSVOD19a (a gift from Dr. E. Blair). The TRP-1 leader sequence
FIGURE 1 – A TRP-1/lacZ fusion gene in transgenic mice. (a) The
TRP-1/lacZ fusion construct. B 5 BamHI, E 5 EcoRI, X 5 XbaI, S 5
SalI. (b,c) E10.5 embryo (b) and E12.5 embryo (c) transgenic for
TRP-1/lacZ and stained with Xgal. (d) Section through eye of an E12.5
embryo, transgenic for TRP-1/lacZ and stained with Bluogal. Expres-
sion from TRP-1 promoter is restricted to the developing RPE. No
signal is seen in the neuroretina (NR).
FIGURE 2 – Transgenic mice carrying a TRP-1/ret fusion gene. (a) Scheme of the TRP-1/ret fusion gene used for microinjection. The construct
contains 4 kb TRP-1 promoter, the ret transforming gene and SV40 small T splice and polyadenylation sequences. Probes used in Southern blot are
indicated by gray bars. Location of PCR primers 1, 2 and 3 is depicted by arrows. K 5 KpnI, X 5 XhoI, E 5 EcoRI, N 5 NotI. (b) Southern blot
analysis of a TRP-1/ret transgenic mouse (Tg). EcoRI digests of tail DNA were hybridized [probes in (a)] resulting in a 1.1 kb fragment and a 1.7
kb fragment. wt 5 wild type (non-transgenic littermate). (c,d) Analysis of transgenic expression. PCR analysis of DNA and RNA of TRP-1/ret
transgenic mouse using primers 2 and 3, on both sides of the SV40 small T intron. Amplification of genomic DNA results in a longer fragment (208
bp). RT-PCR from total RNA of TRP-1/ret transgenic eye results in a shorter fragment [141 bp; depicted by asterisk in (d)]. Transgenic expression
is seen in adult eyes (lanes 1,2) and E12.5 embryo (lane 4). M 5 molecular weight marker V (Boehringer Mannheim, Germany). Lanes 3,6:
Genomic DNA, transgenic. Lane 5: RNA, E12.5 embryo, non-transgenic. (e,f) Eye sections (E12.5 embryo) analyzed by immunofluorescence for
expression of ret. No distinct signal is recognized in eye of wild-type littermate (e), but detected in RPE of transgenic embryo (f). NR 5
neuroretina. (g) Microphthalmia in TRP-1/ret transgenic mice: Wild-type mouse (left) and transgenic littermate (right, 3 weeks old, line 152).
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and promoter extends between a BamHI site located around 4 kb
upstream of the transcription initiation site and a PvuII site at
1107. The entire TRP-1 promoter and leader sequence was placed
in pSVoD19a upstream from the TRP-1 first intron. A residual
BamHI site located in the pSVoD polylinker was destroyed by
partial digestion with BamHI followed by treatment with Klenow.
The entire TRP-1/lacZ construct was excised as a BamHI fragment.
TRP-1/ret fusion construct
A HindIII-PvuI fragment of construct MT/ret (Iwamoto et al.,
1991) (kindly provided by Dr. T. Iwamoto) containing 2.7 kb of ret
cDNA and 1.7 kb of SV40 small T splice and polyadenylation
sequence was cloned into HindIII and EcoRV sites of pBluescript
IISK2 (Stratagene, La Jolla, CA). A 4 kb BamHI fragment of the
murine TRP-1 promoter, extending up to 1107 of the TRP-1 gene
(kindly provided by Dr. I. Jackson), was inserted 58 to ret into the
HindIII site. The construct was deliberated from vector sequences
by digestion with KpnI and NotI.
Generation and analysis of transgenic mice
Transgenic constructs were released from vector sequences by
cleavage with BamHI (TRP-1/lacZ) or KpnI and NotI (TRP-1/ret),
purified from agarose gels using silica powder and injected into
fertilized oocytes derived from mating of CB6 (BALB/c 3 C57BL/
6J) F1 females and males, or NMRI mice (obtained from Harlan,
Horst, The Netherlands). Production of transgenic mice followed
established procedures. They were identified by Southern blot
analysis or PCR analysis of genomic DNA isolated from tail
biopsies (Schmidt et al., 1998). For lacZ, we used a probe derived
from lacZ coding sequence (not shown), and for PCR analysis, a
sense primer located at the 58 end of exon 2 of TRP-1
(58-agagcagcataggagacc-38, position 1186–1205) and an antisense
primer in the lacZ gene; 2 of 4 identified founders (822 and 825)
transmitted the transgene, and transgenic lines were established by
breeding to non-transgenic NMRI mice. b-Galactosidase staining
of embryos was performed essentially as described using Xgal or
Bluogal (Schmidt et al., 1998).
For genotyping of TRP-1/ret transgenic mice by Southern blot
analysis, we used a probe derived from SV40 splice and polyade-
nylation sequence or an EcoRI-BglII fragment of ret cDNA
(Iwamoto et al., 1991). PCR analysis was performed using an
upstream primer in ret (P1, 58-tcccttccacatggattgaa-38; position
2354–2373 of ret) and a downstream primer (P3) 38 to the SV40
intron (58-ggcatttcttctgagcaa-38, position 4489–4506 of SV40
DNA). Using PCR and/or Southern blot analysis, a total of 9
founders were identified (Table I). For RT-PCR analysis, total RNA
was prepared from adult eyes or embryonic head and reverse
transcription (RT)-PCR was performed as described (Schmidt et
al., 1998) using primer P3 and an upstream primer (P2) 58 to the
SV40 intron (58-cttacttctgtggtgtga-38, position 4696–4679 of SV40
DNA).
To generate TRP-1/ret transgenic mice on a KitW-v/KitW-v mutant
background, KitW-v/1 females (obtained from Jackson Laboratory,
Bar Harbor, ME) were mated to TRP-1/ret transgenic males.
KitW-v/1 TRP-1/ret transgenic mice were further bred to KitW-v/1
mice. The different KitW-v genotypes were distinguished by pheno-
type (KitW-v/1: white spotting on belly; KitW-v/KitW-v: black-eyed
white).
Histology
Embryos were obtained from timed breedings to CB6F1 mice,
with the morning of the appearance of a vaginal plug considered
E0.5. They were removed from the surrounding decidua, fixed in
4% paraformaldehyde, 13 phosphate-buffered saline (PBS) and
embedded in methacrylate (immunobed kit solution, Polyscience,
Warrington, PA); 6–7 µm sections were cut and stained with
Giemsa (Merck, Darmstadt, Germany). Sections from eyes of
newborn or 7-day-old mice were treated accordingly. Sectioning of
Xgal- or Bluogal-stained embryos was performed as described
(Schmidt et al., 1998; Tief et al., 1996). For immunofluorescence,
cryostat sections were fixed for 3 min in ice-cold acetone, blocked
in PBS/1% bovine serum albumin (BSA) and incubated with
primary antibodies. TRP-1 and tyrosinase were detected using
antibodies aPEP1 and aPEP7 (kindly provided by Dr. V. Hearing).
For ret we used anti-ret(tk) antibody generated against the tyrosine
kinase domain of human ret (kindly provided by M. Santoro). For
detection of Mi protein, we used a polyclonal antibody kindly
provided by H. Arnheiter. Goat anti-rabbit CY3 antibody was used
as secondary antibody (Jackson ImmunoResearch, West Grove,
PA).
RESULTS
TRP-1 promoter directs expression to
the developing RPE in transgenic mice
To investigate the TRP-1 promoter in transgenic mice and to
compare its activity with the tyrosinase promoter, a TRP-1/lacZ
fusion gene was constructed containing 4 kb of TRP-1 upstream
sequences (Fig. 1). Two stable transgenic lines were established
and analyzed. Consistent and reproducible expression was ob-
served (Fig. 1) in the developing eye, from E10.5 onward
(Raymond and Jackson, 1995). Expression of b-galactosidase was
localized in the outer layer of the optic cup, the presumptive RPE
(Fig. 1). Compared with tyrosinase-lacZ transgenic mice, the signal
was much more intense. We therefore suggest that 4 kb of the
TRP-1 promoter provides specific and strong transgene expression
in the developing RPE.
Microphthalmia in TRP-1/ret transgenic mice
Ret sequence (derived from MT-ret, Iwamoto et al., 1991) was
ligated to 4 kb TRP-1 promoter sequences and used for generation
of transgenic mice (Fig. 2a). Nine transgenic mouse lines were
identified by PCR or Southern blot analysis (Fig. 2b,c, Table I).
Transgenic ret expression (hereafter: TRP-1/ret) was analyzed by
RT-PCR using intron-spanning primers, and detected in embryos
and eyes of adult mice (Fig. 2c,d). To verify that TRP-1/ret
transcripts result in protein expression in the developing RPE, we
performed immunofluorescence staining on eye sections. Specific
staining was detected in the RPE of a transgenic embryo (Fig. 2f )
and absent in the RPE of a non-transgenic littermate (Fig. 2e). Four
founders (3, 151, 152, 161) exhibited microphthalmia and closed or
slightly closed eyelids (Fig. 2g). They were bred to generate stable
lines. Founder 4 exhibited increased eye size, but all transgenic
offspring of founder 4 were microphthalmic. Offspring of line 34
were macrophthalmic with eye size increasing in adulthood.
However, mating of transgenic males and females resulted in mice
with a microphthalmic phenotype. It is feasible that low expression
or delayed expression of TRP-1/ret is not sufficient to interfere with
early eye development, but is nevertheless capable of influencing
retina and eye development at later stages. We have observed the
microphthalmic phenotype reproducibly in several independent
lines, and further concentrated on these lines. We conclude that
expression of TRP-1/ret in the RPE of transgenic mice results in
microphthalmia.
TABLE I – TRP-1/RET TRANSGENIC MOUSE LINES DEVELOP








3 5–10 Closed eyelids, sM 1
4 ND Enlarged eyes in founder, offspring sM
with closed eyelids
ND
34 2 Enlarged eyes, some offspring with mM 1
151 3–5 Lids open, mM 1
152 10–20 Closed eyelids, sM 1
161 5–10 Closed eyelids, sM 1
1Three other lines (38, 42, 153) showed no obvious phenotype. sM 5
severe microphthalmia, eyes always closed; mM 5 mild microphthal-
mia, lids open; ND 5 not determined.
602 SCHMIDT ET AL.
Ret affects development of the RPE and induces proliferation
Further analyses on eye development and RPE were performed
on lines 3, 152 and 161, which exhibit similar microphthalmic
phenotype (Table I). In these transgenic mouse lines, no alterations
in skin or internal organs were observed. In wild-type mice, the
developing RPE is composed of one cell layer (Fig. 3a,c). In the
transgenic eye, already at E10.5 the presumptive RPE is thickened
and consists of more than one layer of elongated cells (Fig. 3b). At
E12.5, RPE cells proliferated into the intraretinal space, most often
in the region of the presumptive ciliary epithelium. At this stage,
the RPE had changed to a thick and stratified epithelium, with 2 or
more cell layers (Fig. 3d). The presence of the tumor and/or the
changes in the RPE might prevent closure of the choroid fissure and
thereby cause failure to build up intraocular pressure. This might
explain the development of the microphthalmic phenotype. The
proliferation is originating from the RPE, as apparent from
embryos bitransgenic for TRP-1/lacZ and TRP-1/ret, which were
stained for b-galactosidase activity (Fig. 3e,f ). In the RPE of E12.5
embryos, TRP-1/lacZ expression is detected in the stratified
epithelium of the transgenic RPE and in the proliferating cells that
are in continuation with the RPE. This furthermore demonstrates
that the TRP-1 (24 kb) promoter, which regulates expression of
both lacZ and ret, is still active at this developmental stage, even
though pigmentation and expression of pigmentation genes might
already be affected (see below). In E15.5 embryos, the tumor is
much more prominent and pigmented (not shown). The RPE is still
present and recognizable as stratified epithelium with absent or
reduced pigmentation.
We asked whether expression of melanogenic enzymes is
affected in early eye development. In the thickened and stratified
epithelium, pigmentation is reduced or absent (Figs. 3, 4). Pigmen-
tation was only visible in some RPE cells. Tyrosinase and TRP-1,
which are enzymes involved in melanin biosynthesis, are present in
the RPE of non-transgenic littermates (Fig. 4b,c). In the transgenic
RPE, both proteins were only detected in still pigmented cells, but
absent in unpigmented RPE (Fig. 4e–g). The transcription factor
microphthalmia (Mi), which is important for RPE development and
is involved in regulation of tyrosinase and TRP-1 gene transcrip-
tion (for review see Zhao et al., 1997), was detected in both
transgenic and non-transgenic RPE (Fig. 4d,h). We therefore
suggest that the effects on pigmentation and expression of TRP-1
and tyrosinase are not due to decreased expression of Mi.
Tumor formation after birth
Proliferation of RPE was also visible after birth in newborns
(Fig. 5a,b) and in 7-day-old mice (Fig. 5c–f ). In these mice, the
resulting tumors were in continuation with the RPE and were often
heavily pigmented (Fig. 5f ). In older mice, tumors increased in size
(not shown), but remained benign, and no metastases have been
detected to date. In 7-day-old mice, the neuroretina was folded and,
at some places, formed double layers with 2 ganglion cell layers
directly facing each other (Fig. 5d). All layers had formed in the
neuroretina (Fig. 5e). This is striking since the RPE itself was
already affected early in development and was still present as
unpigmented thickened epithelium (Fig. 5d,e). No alterations in the
choroidal layer were detected in newborns or 7-day-old mice. In
FIGURE 3 – Development of RPE in TRP-1/ret transgenic mice. (a) E10.5, wild type. (b) E10.5, TRP-1/ret transgenic. (c) E12.5, wild type. (d)
E12.5, transgenic. (e) E12.5, TRP-1/lacZ transgenic embryo, stained with Xgal. (f) E12.5, double transgenic (TRP-1/ret and TRP-1/lacZ)
littermate, stained with Xgal. Arrows indicate proliferations into intraretinal space positive for b-galactosidase activity. NR 5 neuroretina,
L 5 lens, ON 5 optic nerve.
FIGURE 4 – Expression of tyrosinase and TRP-1 is affected by ret
expression. (a–d) E12.5, wild type. (e–h) E12.5, TRP-1/ret transgenic
littermate. Eye sections [brightfield (a,e)] were analyzed by immunoflu-
orescence for expression of tyrosinase (b,f), TRP-1 (c,g) and Mi protein
(d,h). Tyrosinase and TRP-1 expression is reduced or absent in the
transgenic RPE, and maintained in cells that are pigmented [asterisks in
(e–g)]. NR 5 neuroretina.
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addition, eye tumors were also observed in TRP-1/ret transgenic
mice (line 161), which had been bred onto a KitW-v/KitW-v mutant
background (not shown). The KitW-v mutation is characterized by
deficiency in neural crest-derived melanocytes (MacKenzie et al.,
1997). This gives further evidence that the tumor is derived from
the RPE. We thus conclude that ret expression affected the structure
of RPE and induced proliferation of RPE cells in the developing
mouse eye. Consequently, this leads to RPE tumor formation and
severe malformation of the eye after birth.
DISCUSSION
Tyrosinase, TRP-1 and TRP-2 are expressed in melanocytes
derived from the neural crest and in the RPE. The tyrosinase
promoter has been used successfully in transgenic mouse experi-
ments and leads to transgenic expression in pigment cells. The
expression levels are rather low and experiments using tyrosinase-
lacZ fusion constructs, which contained 6 kb of 58 regulatory
sequence, have shown that this promoter is also active in the
developing and adult forebrain (Schmidt et al., 1998; Tief et al.,
1996). The TRP-2 (Dct, dopachrome tautomerase) promoter was
analyzed in TRP-2/lacZ transgenic mice and has been demon-
strated to efficiently target expression to both RPE and melanoblasts/
melanocytes. It is also expressed in the developing telencephalon
(MacKenzie et al., 1997). Analysis of a TRP-1/lacZ fusion gene in
transgenic mice clearly showed that 4 kb of the TRP-1 promoter is
sufficient for specific and high expression of the transgene in the
developing RPE (Fig. 1; Raymond and Jackson, 1995). Even
though TRP-1 is expressed in melanocytes, we did not detect any
b-galactosidase expression in melanocytes, which suggests the
existence of further regulatory elements not retained within the 4
kb promoter. Nevertheless, this specific expression pattern renders
the promoter extremely suitable to target transgenes to the RPE.
In the TRP-1/ret transgenic mice, expression of the transgene
was observed in the developing RPE and the eye tumor (Fig. 2).
Additional evidence suggests that the effects are caused by
expression in RPE only and that transgenic expression is absent or
very low in melanocytes: (1) no b-galactosidase expression was
detected in melanocytes of TRP-1/lacZ transgenic mice (Fig. 1;
Raymond and Jackson, 1995); (2) microphthalmia and tumors were
observed in several independent TRP-1/ret transgenic mouse lines
(Table I), thus excluding a possible effect by the transgenic
insertion site; (3) the phenotype is seen in embryonic eyes (e.g.,
Fig. 3), at an embryonic age when choroidal melanocytes are not
yet present; (4) TRP-1/ret expression was not able to compensate
for kit deficiency (KitW-v/KitW-v) in melanocytes in 2 different
transgenic lines (161, 34) which showed tumors and eye phenotype
(not shown). Such a rescue of KitW-v-mutant melanocytes has been
reported in MT/ret transgenic mice (Iwamoto et al., 1991).
When targeting the ret oncogene specifically to the developing
RPE, the observed phenotypes in the eye (besides tumor formation)
are reminiscent of mutations at the Mi gene locus. In mice, at least
17 mutant alleles of microphthalmia are known. All of them show
defects in neural crest-derived melanocytes, and some also in the
RPE (Moore, 1995; Zhao et al., 1997). From the resemblance of the
phenotypes between the TRP-1/ret transgenic mice and the de-
scribed mutations at the microphthalmia locus (microphthalmic
phenotype, thickened RPE, decreased pigmentation) we speculated
that ret interferes with activity of the Mi transcription factor in the
RPE. However, Mi immunoreactivity was still detected while
pigment production was reduced. Thus, the decreased pigmentation
and the morphological change of the RPE seem not to be caused by
reduced expression of Mi.
In humans, dominant gain-of-function mutations of RET are
associated with multiple endocrine neoplasia and familial medul-
lary thyroid carcinoma (Edery et al., 1997). When targeted to
transgenic mice, RET/PTC1 resulted in tumor formation (Portella
et al., 1996; Santoro et al., 1996). Tumorigenic activity of ret has
been reported in MT/ret, MMTV/ret and Eµ/ret transgenic mouse
lines, and led to adenocarcinomas of mammary and salivary glands
(Iwamoto et al., 1990), melanocytic tumors (Iwamoto et al., 1991)
or pro-B-cell leukemia (Wasserman et al., 1998). In TRP-1/ret, the
tripartite motif of the rfp (ret finger protein) gene, which is involved
FIGURE 5 – RPE and eye are affected after birth. (a) Newborn, non-transgenic. (b) Newborn, TRP-1/ret transgenic littermate. Arrow depicts
tumor formation in front of eye. (c–f) Seven days, TRP-1/ret transgenic eye with tumor formation and folding of neuroretina. (d) Magnification of
(c) showing folding of neuroretina. (e) Section through neuroretina showing 2 layers of unpigmented RPE and apparently normal organization of
the neuroretina. (f) Magnification of (c) showing pigmented RPE tumor. NR 5 neuroretina, L 5 lens.
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in protein-protein interaction and intracellular localization, is still
retained (Cao et al., 1997). It is assumed that ret (rfp-ret) causes
cellular transformation by activating ret kinase activity, thus
leading to proliferation. Alternatively, nuclear localization of the
rfp-ret fusion gene might lead to dimerization with endogenous rfp,
thereby interfering with normal unknown function of rfp.
In the TRP-1/ret transgenic mouse lines, tumors and proliferative
activity were observed in the RPE, but proliferation started more
often in the anterior part (Figs. 3, 5b). This might be explained by
increased expression levels, earlier onset of expression or absence
of an overlaying functional neuroretina. At birth, melanization in
the RPE is mainly terminated and, hence, expression of TRP-1 (and
tyrosinase and TRP-2) does cease thereafter. Therefore, the expres-
sion of the transgene might not be sufficient to cause tumor
formation at all sites of the RPE. In transgenic mice carrying the
RET/PTC1 transgene, controlled by the 58 region of the H4 gene,
only a limited number of tumor types (derived from mammary or
sebaceous glands) was observed, even though higher expression
levels were detected in other tissues (Portella et al., 1996). Here,
the authors suggested that RET/PTC1 was able to transform only
certain cell types, in particular glandular structures. In neuroblas-
toma cells, activated RET can suppress proliferation and results in
acquisition of a differentiated phenotype (D’Alessio et al., 1995).
Hence, reduction or absence of tumor formation in certain parts of
the RPE would indicate that these areas are less susceptible to the
activation of ret and only react by forming a stratified epithelial
layer. In the tumors (Fig. 5), certain RPE-derived cells show
production of pigment while neighboring RPE is unpigmented due
to prevention of normal differentiation. However, some cells in the
tumor may have ceased expression of the transgene, stopped
proliferation and begun to reestablish characteristics of RPE cells,
such as pigment production, similar to reports on physical injuries
of the RPE (for review see Zhao et al., 1997).
The TRP-1 promoter was effective in targeting genes specifically
to the RPE of the developing eye. In TRP-1/DT-A transgenic mice,
ablation of the RPE resulted in disorganization of the neuroretina.
Retinal layers were maintained in places adjacent to pigmented
areas of the RPE (Raymond and Jackson, 1995). In TRP-1/Tag
(SV40 T antigen) transgenic mice, tumors developed from the RPE
without affecting early development of this layer (Penna et al.,
1998). In contrast with the tumors observed in the TRP-1/ret
transgenic mice, eye tumors in the TRP-1/Tag transgenic mice were
malignant and invaded along the optic nerve and into the brain.
Moreover, TRP-1/Tag RPE tumor cells metastasized to inguinal
lymph nodes and spleen. It is known that expression of SV40 T
antigen can cause alterations that are irreversible and lead to
maintenance of the transformed state. Thus, it is conceivable that
ret expression in the RPE is not sufficient or not sufficiently high to
induce similar changes. This might explain why the tumors stay
benign and do not affect survival of transgenic mice.
In summary, our results show that TRP-1/ret transgenic expres-
sion prevents normal differentiation of the RPE and induces
proliferation and tumor formation of the RPE. These changes in the
RPE lead to microphthalmia and severely affect eye development.
This is important and demonstrates that a normally developed RPE
is absolutely required for eye development and eye structure. In
addition, these mice might be useful models for defects of human
eye development, i.e., blindness, eye tumor formation and microph-
thalmia.
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